TOKYO -- Ricoh will acquire U.S.-based biotechnology startup Elixirgen Scientific as early as July in a push to turn messenger RNA technology into a core business, Nikkei has learned.
Known largely for office equipment like printers, Ricoh acquired a 34.5% stake in Elixirgen back in 2019. The Japanese company now looks to a become majority owner of the startup in a new deal estimated to be worth billions of yen, or tens of millions of dollars, entering the business of contract production for mRNA pharmaceuticals.
